Skip to main content
SpringerLink
Log in
  • Wissenschaft und Praxis — Gedankenaustausch zu aktuellen Fragen
  • Kontaktstudium in Zusammenarbeit mit dem USW Universitätsseminar der Wirtschaft
  • Published:

Lohnt sich für Pharmaunternehmen der Markteintritt als Late Mover? — Ergebnisse einer Rentabilitätsanalyse

Schmalenbachs Zeitschrift für betriebswirtschaftliche Forschung volume 53, pages 632–648 (2001)Cite this article

Summary

This paper describes a comprehensive profitability analysis of late mover products in a large segment of the global market for cardiovascular drugs. The study is based on the estimation and classification of over 200 product life cycles from four global cardiovascular product categories which leads to different life cycles for the pioneer as well as early follower products on the one hand and late mover products on the other hand. The order of entry, thus, is not only crucial to achieve a certain market share level but also to the shape of the drug life cycle and finally for the long term economic evaluation of innovative products. The paper provides first findings on this subject through a simulation study which is in line with previous research designs and shows the impact of the product life cycle shape on the net present value. The effects of relative changes in several input values on net present value are investigated in a sensitivity analysis. The computation of selected point elasticities reveals the potential impact decisions on marketing mix variables like price and promotional effort can have.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Literaturverzeichnis

  • Baber, W. R./ Kang, S.-H. (1996): Estimates of Economic Rates of Return for the U.S. Phamaceutical Industry, 1976–1987, in: Journal of Accounting and Public Policy, 15, S. 327–346.

    Article  Google Scholar 

  • Bauer, H. H./ Fischer, M. (2000): Die empirische Typologisierung von Produktlebenszyklen und ihre Erklärung durch die Markteintrittsreihenfolge, in: Zeitschrift für Betriebswirtschaft, 70, S. 937–958.

    Google Scholar 

  • Bauer, H. H./ Fischer, M./ Verspagen, R. (1999): Determinanten des ‘Line Extension’-Erfolgs, Ergebnisse einer empirischen Studie, in: Die Pharmazeutische Industrie, 61, S. 796–803.

    Google Scholar 

  • Berndt, E./ Bui, L. T./ Reiley, D. H./ Urban, G. L. (1994): The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry, Working Paper #19-94, Sloan School, MIT.

  • Bierly, P./ Chakrabarti, A. (1996): Determinants of Technology Cycle Time in the U.S. Pharmaceutical Industry, in: R&D Management, 26, S. 115–126.

    Article  Google Scholar 

  • Bond, R. S./ Lean, D. F. (1977): Sales Promotion and Product Differentiation in Two Prescription Drug Markets, Federal Trade Commission, Washington DC.

    Google Scholar 

  • Bowman, D./ Gatignon, H. (1996): Order of Entry as a Moderator of the Effect of the Marketing Mix on Market Share, in: Marketing Science, 15, S. 222–242.

    Article  Google Scholar 

  • Buzzell, R. D./Gale, B. T. (1989): Das PIMS-Programm: Strategien und Unternehmenserfolg.

  • DiMasi, J. A. (1995): Success Rates for New Drugs Entering Clinical Testing in the United States, in: Clinical Pharmacology & Therapeutics, 58, S. 1–14.

    Article  Google Scholar 

  • DiMasi, J. A./ Grabowski, H. G./ Vernon, J. M. (1995): R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry, in: International Journal of the Economics of Business, 2, S. 201–219.

    Article  Google Scholar 

  • DiMasi, J. A./ Hansen, R. W./ Grabowski, H. G./ Lasagna, L. (1995): Research and Development Costs for New Drugs by Therapeutic Category, in: PharmacoEconomics, 7, S. 152–169.

    Article  Google Scholar 

  • DiMasi, J. A./ Hansen, R. W./ Grabowski, H. G./ Lasagna, L. (1991): Cost of Innovation in the Pharmaceutical Industry, in: Journal of Health Economics, 10, S. 107–142.

    Article  Google Scholar 

  • Grabowski, H. G./ Vernon, J. (1994): Returns to R&D on New Drug Introductions in the 1980s, in: Journal of Health Economics, 13, S. 384–406.

    Article  Google Scholar 

  • Grabowski, H. G./ Vernon, J. (1990): A New Look at the Returns and Risks to Pharmaceutical R&D, in: Management Science, 36, S. 804–821.

    Article  Google Scholar 

  • Grabowski, H. G./ Vernon, J. (1982): A Sensitivity Analysis of Expected Profitability of Pharmaceutical Research and Development, in: Managerial and Decision Economics, 3, S. 36–40.

    Article  Google Scholar 

  • Graves, S. B./ Langowitz, N. S. (1993): Innovative Productivity and Returns to Scale in the Pharmaceutical Industry, in: Strategic Management Journal, 14, S. 593–605.

    Article  Google Scholar 

  • Jensen, E. J. (1987): Research Expenditures and the Discovery of New Drugs, in: Journal of Industrial Economics, 36, S. 83–95.

    Article  Google Scholar 

  • Joglekar, P./ Patterson, M. L. (1986): A Closer Look at the Returns and Risks of Pharmaceutical R&D, in: Journal of Health Economics, 5, S. 153–177.

    Article  Google Scholar 

  • Kalyanaram, G./ Robinson, W. T./ Urban, G. L. (1995): Order of Market Entry: Established Empirical Generalizations, Emerging Empirical Generalizations, and Future Research, in: Marketing Science, 14, part 2 of No. 3, G212–G221.

    Article  Google Scholar 

  • Mansfield, E. (1987): Price Indexes for R and D Inputs, 1969–1983, in: Management Science, 33, S. 124–129.

    Article  Google Scholar 

  • Mattison, N./ Trimble, A. G./ Lasagna, L. (1988): New Drug Development in the United States, 1963–1984, in: Clinical Pharmacology & Therapeutics, 43, S. 15–27.

    Article  Google Scholar 

  • Myers, S. C./ Howe, C. D. (1997): A Life Cycle Financial Model of Pharmaceutical R&D, Working Paper #41-97, MIT.

  • Myers, S. C./ Shyam-Sunder, L. (1996): Cost of Capital Estimates for Pharmaceutical Research and Development, in: Helms, R. D. (ed.): Competitive Strategies in the Pharmaceutical Industry, American Enterprise Institute, Washington, DC.

    Google Scholar 

  • OTA; U.S. Congress, Office of Technology Assessment (1993): Pharmaceutical R&D: Costs, Risks, and Rewards, Washington, U.S. Government Printing Office.

    Google Scholar 

  • Robinson, W. T./ Kalyanaram, G./ Urban, G. L. (1994): First-Mover Advantages from Pioneering New Markets: A Survey of Empirical Evidence, in: Review of Industrial Organization, 9, S. 1–23.

    Article  Google Scholar 

  • Sheck, L./ Cox, C./ Davis, H. T./ Trimble, A. G./ Wardell, W. M./ Hansen, R. W. (1984): Success Rates in the United States Drug Development System, in: Clinical Pharmacology & Therapeutics, 36, S. 574–583.

    Article  Google Scholar 

  • Szymanski, D. M./ Troy, L. C./ Bharadwaj, S. J. (1995): Order of Entry and Business Performance: An Empirical Synthesis and Reexamination, in: Journal of Marketing, 59 (Winter), S. 17–33.

    Article  Google Scholar 

  • Urban, G. L./ Carter, T./ Gaskin, S./ Mucha, Z. (1986), Market Share Rewards to Pioneering Brands: An Empirical Analysis and Strategic Implications, in: Management Science, 32, S. 645–695.

    Article  Google Scholar 

  • Wiggins, S. (1987): The Cost of Developing a New Drug, Pharmaceutical Manufacturers Association, Washington, DC.

    Google Scholar 

  • Woltman, H. R. (1989): Reviewing the Bidding: R&D Costs and Profitybility of New Chemical Entities, in: Journal of Research in Pharmaceutical Economics, 1, S. 49–65.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lehrstuhl für Allgemeine Betriebswirtschaftslehre und Marketing II, Universität Mannheim, L 5, 1, 68131, Mannheim, Deutschland

    Hans H. Bauer

  2. McKinsey & Company, Kurfürstendamm 185, 10707, Berlin, Deutschland

    Marc Fischer

  3. Roche Diagnostics GmbH, Mannheim, Deutschland

    Volker Pfahlert (Mitglied der Geschäftsführung mit dem Zuständigkeitsbereich Vertrieb Deutschland)

Authors
  1. Hans H. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Volker Pfahlert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bauer, H.H., Fischer, M. & Pfahlert, V. Lohnt sich für Pharmaunternehmen der Markteintritt als Late Mover? — Ergebnisse einer Rentabilitätsanalyse. Schmalenbachs Z betriebswirtsch Forsch 53, 632–648 (2001). https://doi.org/10.1007/BF03372662

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03372662

search

Navigation